---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289234650.md"
description: "Actuate Therapeutics shares are trading higher after the company announced that elraglusib will be evaluated in the BEACON2 clinical trial to identify and advance treatment approaches for children with relapsed and refractory neuroblastoma."
datetime: "2026-06-09T19:52:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289234650.md)
  - [en](https://longbridge.com/en/news/289234650.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289234650.md)
---

# 

Actuate Therapeutics shares are trading higher after the company announced that elraglusib will be evaluated in the BEACON2 clinical trial to identify and advance treatment approaches for children with relapsed and refractory neuroblastoma.

### Related Stocks

- [ACTU.US](https://longbridge.com/en/quote/ACTU.US.md)

## Related News & Research

- [This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday](https://longbridge.com/en/news/294389968.md)
- [Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma | ACTU Stock News](https://longbridge.com/en/news/289185012.md)
- [B Capital invests in pediatric behavioral health provider Flourish Health](https://longbridge.com/en/news/294365281.md)
- [Phoenix Children's Foundation Halves Its Prospecting Time with ZoomInfo | GTM Stock News](https://longbridge.com/en/news/293788761.md)
- [Cingulate Phase 3 ADHD trial results for CTx-1301 published in Journal of Child and Adolescent Psychopharmacology](https://longbridge.com/en/news/294366513.md)